Lucy E Vivash

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2960912/publications.pdf

Version: 2024-02-01

35 papers

1,359 citations

16 h-index 395702 33 g-index

42 all docs 42 docs citations

times ranked

42

2672 citing authors

#	Article	IF	CITATIONS
1	The <scp>ENIGMAâ€Epilepsy</scp> working group: Mapping disease from large data sets. Human Brain Mapping, 2022, 43, 113-128.	3.6	47
2	A systemsâ€level analysis highlights microglial activation as a modifying factor in common epilepsies. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	22
3	Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [<scp>¹⁸F</scp>]â€ <scp>FEMPA PET</scp> Study. Movement Disorders, 2022, 37, 218-224.	3.9	18
4	Topographic divergence of atypical cortical asymmetry and atrophy patterns in temporal lobe epilepsy. Brain, 2022, 145, 1285-1298.	7.6	18
5	Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: A MELD study. Epilepsia, 2022, 63, 61-74.	5.1	36
6	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.8	24
7	Machine learning approaches for imagingâ€based prognostication of the outcome of surgery for mesial temporal lobe epilepsy. Epilepsia, 2022, 63, 1081-1092.	5.1	10
8	A phase 1b openâ€label study of sodium selenate as a diseaseâ€modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12299.	3.7	7
9	Eventâ€based modeling in temporal lobe epilepsy demonstrates progressive atrophy from crossâ€sectional data. Epilepsia, 2022, 63, 2081-2095.	5.1	11
10	Cognitive profiles in patients with epileptic and nonepileptic seizures evaluated using a brief cognitive assessment tool. Epilepsy and Behavior, 2021, 115, 107643.	1.7	4
11	Artificial intelligence for classification of temporal lobe epilepsy with ROI-level MRI data: A worldwide ENIGMA-Epilepsy study. NeuroImage: Clinical, 2021, 31, 102765.	2.7	25
12	Assessment of the DTIâ€ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. Journal of Neuroimaging, 2021, 31, 569-578.	2.0	68
13	The effect of injection time on rates of epileptogenic zone localization using SISCOM and STATISCOM. Epilepsy and Behavior, 2021, 118, 107945.	1.7	6
14	Low prevalence of amyloid and tau pathology in drugâ€resistant temporal lobe epilepsy. Epilepsia, 2021, 62, 3058-3067.	5.1	8
15	Development of [18F]MIPS15692, a radiotracer with inÂvitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. European Journal of Medicinal Chemistry, 2021, 226, 113822.	5.5	5
16	Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. Brain Imaging and Behavior, 2021, 15, 2795-2803.	2.1	2
17	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021, 11, e055019.	1.9	4
18	Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer's disease: an open-label extension study. BMJ Neurology Open, 2021, 3, e000223.	1.6	7

#	Article	IF	Citations
19	A phase 1b open label study of sodium selenate as a diseaseâ€modifying treatment for behavioural variant frontoâ€temporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
20	Network-based atrophy modeling in the common epilepsies: A worldwide ENIGMA study. Science Advances, 2020, 6, .	10.3	97
21	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	1.9	11
22	White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA-Epilepsy study. Brain, 2020, 143, 2454-2473.	7.6	123
23	A phase 1B openâ€labelled study of sodium selenate as a disease modifying treatment for possible behavioural variant frontoâ€ŧemporal dementia. Alzheimer's and Dementia, 2020, 16, e039192.	0.8	1
24	Neurofilament light chain in psychiatric and neurodegenerative disorders: A â€̃câ€reactive protein' for the brain?. Alzheimer's and Dementia, 2020, 16, e041347.	0.8	1
25	Ictal cerebral blood flow in psychogenic non-epileptic seizures: a preliminary SPECT study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2018-320173.	1.9	4
26	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	4.4	69
27	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. Annals of Neurology, 2019, 85, 241-250.	5.3	25
28	Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain, 2018, 141, 391-408.	7.6	352
29	A Phase IIa Randomized Control Trial ofÂVEL015 (Sodium Selenate) inÂMild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 223-232.	2.6	53
30	Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?. Journal of Nuclear Medicine, 2016, 57, 165-168.	5.0	145
31	Semiâ€automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. Journal of Magnetic Resonance Imaging, 2015, 42, 1631-1638.	3.4	9
32	In Vivo Measurement of Hippocampal GABAA/cBZR Density with [18F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy. PLoS ONE, 2014, 9, e86722.	2.5	22
33	¹⁸ F-Flumazenil: A γ-Aminobutyric Acid A–Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy. Journal of Nuclear Medicine, 2013, 54, 1270-1277.	5.0	61
34	Changes in hippocampal GABAA/cBZR density during limbic epileptogenesis: Relationship to cell loss and mossy fibre sprouting. Neurobiology of Disease, 2011, 41, 227-236.	4.4	19
35	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 958-965.	6.4	22